Resources
33 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 11/17/2023 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration (SAMHSA) has published the new resource "Counseling Approaches To Promote Recovery From Problematic Substance Use and Related Issues". This Treatment Improvement Protocol (TIP) provides guidance to counselors, administrators, and supervisors about recovery-oriented services, supports, and care, allowing them to better serve individuals in or seeking recovery from problematic substance use.
Posted 11/9/2023 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration (SAMHSA) published Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants in 2018. The National Center on Substance Abuse and Child Welfare (NCSACW) developed companion materials that offer information and strategies to support pregnant and parenting people with substance use disorders (SUDs) in the child welfare system.
Posted 11/9/2023 (updated 3/28/2024)
The Recovery-Ready Workplace Toolkit: Guidance and Resources for Private and Public Sector Employers was created through the efforts of the Office of National Drug Control Policy, the Domestic Policy Council, and 12 federal departments and independent agencies. It is designed to help businesses and other employers prevent and respond more effectively to substance misuse among employees, build their workforces through hiring of people in recovery, and develop a recovery-supportive culture.
Posted 9/4/2023 (updated 3/26/2024)
Two reports are now available from Fors Marsh, a research and communications firm who's reports work to highlight system problems like SUD. The "Road Map for Advancing a Recovery-Ready Nation" report examines recovery research and covers issues such as support services, housing, employment, workforce, stigma, etc. The "2022 Workplace Recovery Survey Report" covers background and understanding recovery in the workplace, policies, culture, experiences, and much more.
Posted 8/18/2023 (updated 3/26/2024)
The National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (CCTN) held an event where health care professionals and federal partners discussed xylazine-related testing, treatment, and wound care. As the White House has deemed fentanyl adulterated with xylazine an emerging threat, it is important to identify and adapt to the rapidly changing practices of patient care.
Posted 6/8/2023 (updated 3/27/2024)
There are multiple systems that can help individuals to address substance use disorder (SUD). A new report from the Addiction and Public Policy Initiative of the O’Neill Institute for National and Global Health Law at Georgetown Law Center discusses how these multiple systems are often disjointed which creates barriers for those needing to access services for SUD.
Posted 3/29/2023 (updated 3/27/2024)
The University of Rochester Medicine Recovery Center of Excellence is offering free trainings to provide guidance on evidence-based strategies to work through resistance and encourage help-seeking behavior. Cognitive Behavioral Therapy for Treatment Seeking (CBT-TS) is an evidence-based technique to encourage help seeking among those in need.
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.
Posted 2/14/2023 (updated 3/27/2024)
This systematic review of peer-reviewed literature that held controlled trails which examined a pharmacological treatment for amphetamine/methamphetamine dependence or use disorder. The article found that most studies were underpowered and had low completion rates, with others showing that no pharmacotherapy produced results for the treatment of amphetamine/methamphetamine dependence.
Posted 1/17/2023 (updated 3/27/2024)
The Consolidated Appropriations Act of 2023 removed the federal requirement for providers to have an X-waiver to prescribe medications for the treatment of OUD. The act amended the Controlled Substances Act. Depending on state law, practitioners who have a current DEA registration with Schedule III authority will be able to prescribe buprenorphine for OUD starting now.